Erratum to: Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer

被引：0
|
作者：
Akiko Ogiya
Kieko Yamazaki
Rie Horii
Tadahiko Shien
Yoshiya Horimoto
Norikazu Masuda
Touko Inao
Mitsuchika Hosoda
Naoko Ishida
Tomofumi Osako
Masato Takahashi
Yumi Endo
Yuichiro Miyoshi
Hiroyuki Yasojima
Nobumoto Tomioka
Hiroko Yamashita
机构：
[1] Japanese Foundation for Cancer Research,Breast Surgical Oncology, Cancer Institute Hospital
[2] Cancer Institute of the Japanese Foundation for Cancer Research,Division of Pathology
[3] Okayama University Hospital,Breast and Endocrine Surgery
[4] Juntendo University School of Medicine,Department of Breast Oncology
[5] NHO Osaka National Hospital,Department of Surgery, Breast Oncology
[6] Graduate School of Medical Science Kumamoto University,Department of Breast and Endocrine Surgery
[7] Hokkaido University Hospital,Breast Surgery
[8] Kumamoto City Hospital,Department of Breast and Endocrine Surgery
[9] Kumamoto Shinto General Hospital,Department of Breast Surgery
[10] NHO Hokkaido Cancer Center,Department of Oncology, Immunology and Surgery
[11] Nagoya City University Graduate School of Medical Sciences,undefined
来源：
Breast Cancer | 2017年 / 24卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：642 / 642
相关论文
共 50 条
  • [1] Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer
    Ogiya, Akiko
    Yamazaki, Kieko
    Horii, Rie
    Shien, Tadahiko
    Horimoto, Yoshiya
    Masuda, Norikazu
    Inao, Touko
    Hosoda, Mitsuchika
    Ishida, Naoko
    Osako, Tomofumi
    Takahashi, Masato
    Endo, Yumi
    Miyoshi, Yuichiro
    Yasojima, Hiroyuki
    Tomioka, Nobumoto
    Yamashita, Hiroko
    BREAST CANCER, 2017, 24 (03) : 473 - 482
  • [2] Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer
    Akiko Ogiya
    Kieko Yamazaki
    Rie Horii
    Tadahiko Shien
    Yoshiya Horimoto
    Norikazu Masuda
    Touko Inao
    Mitsuchika Hosoda
    Naoko Ishida
    Tomofumi Osako
    Masato Takahashi
    Yumi Endo
    Yuichiro Miyoshi
    Hiroyuki Yasojima
    Nobumoto Tomioka
    Hiroko Yamashita
    Breast Cancer, 2017, 24 : 473 - 482
  • [3] Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer (vol 24, pg 473, 2017)
    Ogiya, Akiko
    Yamazaki, Kieko
    Horii, Rie
    Shien, Tadahiko
    Horimoto, Yoshiya
    Masuda, Norikazu
    Inao, Touko
    Hosoda, Mitsuchika
    Ishida, Naoko
    Osako, Tomofumi
    Takahashi, Masato
    Endo, Yumi
    Miyoshi, Yuichiro
    Yasojima, Hiroyuki
    Tomioka, Nobumoto
    Yamashita, Hiroko
    BREAST CANCER, 2017, 24 (04) : 642 - 642
  • [4] Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer
    Hiroko Yamashita
    Akiko Ogiya
    Tadahiko Shien
    Yoshiya Horimoto
    Norikazu Masuda
    Touko Inao
    Tomofumi Osako
    Masato Takahashi
    Yumi Endo
    Mitsuchika Hosoda
    Naoko Ishida
    Rie Horii
    Kieko Yamazaki
    Yuichiro Miyoshi
    Hiroyuki Yasojima
    Nobumoto Tomioka
    Breast Cancer, 2016, 23 : 830 - 843
  • [5] Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer
    Yamashita, Hiroko
    Ogiya, Akiko
    Shien, Tadahiko
    Horimoto, Yoshiya
    Masuda, Norikazu
    Inao, Touko
    Osako, Tomofumi
    Takahashi, Masato
    Endo, Yumi
    Hosoda, Mitsuchika
    Ishida, Naoko
    Horii, Rie
    Yamazaki, Kieko
    Miyoshi, Yuichiro
    Yasojima, Hiroyuki
    Tomioka, Nobumoto
    BREAST CANCER, 2016, 23 (06) : 830 - 843
  • [6] T5 Is a New Molecular Predictor of Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Filipits, M.
    Rudas, M.
    Jakesz, R.
    Dubsky, P.
    Singer, C. F.
    Dietze, O.
    Greil, R.
    Jelen, A.
    Sevelda, P.
    Freibauer, C.
    Fitzal, F.
    Mueller, V.
    Jaenicke, F.
    Schmidt, M.
    Koelbl, H.
    Rody, A.
    Kaufmann, M.
    Schroth, W.
    Schwab, M.
    Brauch, H.
    Weber, K.
    Feder, I.
    Hennig, G.
    Gehrmann, M.
    Gnant, M. F. X.
    CANCER RESEARCH, 2010, 70
  • [7] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1176 - 1177
  • [8] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (26): : 2557 - 2570
  • [9] Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Morikawa, Aki
    Henry, N. Lynn
    CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3591 - 3596
  • [10] EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
    K. Almstedt
    S. Mendoza
    M. Otto
    M. J. Battista
    J. Steetskamp
    A. S. Heimes
    S. Krajnak
    A. Poplawski
    A. Gerhold-Ay
    A. Hasenburg
    C. Denkert
    M. Schmidt
    Breast Cancer Research and Treatment, 2020, 182 : 137 - 146
12345